Home / Psoriasis / APremilast After FumaRic Acid Ester Treatment (APART)

APremilast After FumaRic Acid Ester Treatment (APART)


Patient treatment preference and treatment satisfaction of physicians and patients comparing fumaric acid ester therapy with subsequent apremilast treatment

Condition Intervention
Psoriasis Drug: Phase I: Fumaric acid esters. Phase II: Apremilast

Study Type: Observational
Study Design:Observational Model: Other
Time Perspective: Prospective
Official Title:Real-world Benefit of Apremilast Treatment of Patients With Moderate-to-severe Psoriasis After Transition From Fumaric Acid Esters

Resource links provided by NLM:

Further study details as provided by Prof. Kristian Reich, Sciderm GmbH:

Primary Outcome Measures:

  • Mean absolute value of the overall TSQM score at week 24 of apremilast (APR) therapy (phase II). [ Time Frame: 56 weeks ]

Estimated Enrollment:1600
Actual Study Start Date:January 2017
Estimated Study Completion Date:December 2020
Estimated Primary Completion Date:December 2019 (Final data collection date for primary outcome measure)


Check Also

Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation (IMMPRESS)

Study Description Go to  Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information Brief Summary: The purpose of this study is to assess the safety and efficacy of risankizumab compared to placebo in subjects with moderate to severe chronic plaque psoriasis in the Russian Federation. Condition …

Leave a Reply

Your email address will not be published. Required fields are marked *